SCHEMBL21962272

SCHEMBL21962272

N=S(N)(=O)c1ccccc1CN1CCOCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A13 Q16696 5/20 0.53
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 3/20 0.45
CYP2C9 P11712 2/20 0.45
MEN1 O00255 2/20 0.45
ALOX15 P16050 1/20 0.45
HSD17B10 Q99714 1/20 0.45
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
CTSB P07858 1/20 0.43
KDM4E B2RXH2 3/20 0.43
TDP1 Q9NUW8 2/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
NAMPT P43490 1/20 0.41
TSHR P16473 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3362275 0.88 CYP2A13 (0.59) CYP2A13KMT2AALDH1A1CYP2C9MEN1
SCHEMBL28532123 0.82 CYP2A13 (0.55) CYP2A13KMT2AALDH1A1CYP2C9MEN1
SCHEMBL11193326 0.77 CYP2A13 (0.75) CYP2A13KMT2AALDH1A1CYP2C9MEN1
SCHEMBL5251939 0.73 KMT2A (0.49) CYP2A13KMT2AALDH1A1MEN1MAPT
SCHEMBL10642464 0.73 ALDH1A1 (0.50) KMT2AALDH1A1CYP2C9MEN1CYP3A4
SCHEMBL111727 0.73 CYP2A13 (0.64) CYP2A13KMT2AALDH1A1CYP2C9MEN1
SCHEMBL4327006 0.73 MPO (0.75) CYP2A13KMT2AALDH1A1CYP2C9MEN1
SCHEMBL22711364 0.73 CYP2A13 (0.64) CYP2A13KMT2AALDH1A1CYP2C9MEN1
SCHEMBL4108619 0.73 CYP2A13 (0.69) CYP2A13KMT2AALDH1A1CYP2C9MEN1
SCHEMBL2338990 0.73 CYP2A13 (0.64) CYP2A13KMT2AALDH1A1CYP2C9MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3880659-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY Novartis AG (CH) 2021-09-22 EP disclosed
WO-2020102576-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-05-22 WO disclosed